---
title: "Dupixent (dupilumab) in atopic dermatitis: Safety questions"
description: "Safety questions on Dupixent (dupilumab) in atopic dermatitis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings, Monitoring, and Vaccines. Questions: What are the most common side effects of Dupixent for atopic dermatitis? Does Dupixent cause conjunctivitis or other eye side effects? How common are injection site reactions with Dupixent in atopic dermatitis? Does Dupixent raise the risk of eczema herpeticum or shingles (herpes zoster)? 12 further questions follow. 16 questions quoted from 6 sources."
canonical: "https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/safety"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Dupixent (dupilumab) in atopic dermatitis: Safety questions

Manufacturer: sanofi-aventis U.S. LLC; Regeneron Pharmaceuticals, Inc.  
Prescribing information: [Dupixent](https://www.regeneron.com/downloads/dupixent_fpi.pdf)

## Safety

<a id="dupixent-common-side-effects"></a>

### What are the most common side effects of Dupixent for atopic dermatitis?

> “The most common adverse reactions (incidence ≥1%) in patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia.<sup>1</sup>”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Efficacy Results for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety#:~:text=The%20most%20common%20adverse%20reactions,virus%20infection%2C%20dry%20eye%2C%20and)

> “Table 9 summarizes the adverse reactions 
> that occurred at a rate of at least 1% in the DUPIXENT 300 mg Q2W monotherapy groups, and 
> in the DUPIXENT + TCS group, all at a higher rate than in their respective comparator groups 
> during the first 16 weeks of treatment.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 13, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=13)

> “Table 9: 
> Adverse Reactions Occurring in ≥1% of the DUPIXENT Monotherapy 
> Group or the DUPIXENT + TCS Group in the Atopic Dermatitis Trials 
> through Week 16 
> Adverse Reaction 
> DUPIXENT Monotherapy<sup>a</sup> 
> DUPIXENT + TCS<sup>b</sup> 
> DUPIXENT 
> 300 mg Q2W<sup>c</sup> 
>
> N=529 
> n (%) 
> Placebo 
>
>
> N=517 
> n (%) 
> DUPIXENT 
> 300 mg Q2W<sup>c</sup> + TCS 
>
> N=110 
> n (%) 
> Placebo + 
> TCS 
>
> N=315 
> n (%) 
> Injection site reaction 
> 51 (10) 
> 28 (5) 
> 11 (10) 
> 18 (6) 
> Conjunctivitis<sup>d</sup> 
> 51 (10) 
> 12 (2) 
> 10 (9) 
> 15 (5) 
> Blepharitis 
> 2 (<1) 
> 1 (<1) 
> 5 (5) 
> 2 (1) 
> Oral herpes 
> 20 (4) 
> 8 (2) 
> 3 (3) 
> 5 (2) 
> Keratitis<sup>e</sup> 
> 1 (<1) 
> 0 
> 4 (4) 
> 0 
> Eye pruritus 
> 3 (1) 
> 1 (<1) 
> 2 (2) 
> 2 (1) 
> Other herpes simplex 
> virus infection<sup>f</sup> 
> 10 (2) 
> 6 (1) 
> 1 (1) 
> 1 (<1) 
> Dry eye 
> 1 (<1) 
> 0 
> 2 (2) 
> 1 (<1) 
> <sup>a</sup> Pooled analysis of SOLO 1, SOLO 2, and AD-1021. 
> <sup>b</sup> Analysis of CHRONOS where subjects were on background TCS therapy. 
> <sup>c</sup> DUPIXENT 600 mg at Week 0, followed by 300 mg every 2 weeks. 
> <sup>d</sup> Conjunctivitis cluster includes conjunctivitis, allergic conjunctivitis, bacterial conjunctivitis, viral conjunctivitis, 
> giant papillary conjunctivitis, eye irritation, and eye inflammation. 
> <sup>e</sup> Keratitis cluster includes keratitis, ulcerative keratitis, allergic keratitis, atopic keratoconjunctivitis, and 
> ophthalmic herpes simplex. 
> <sup>f</sup> Other herpes simplex virus infection cluster includes herpes simplex, genital herpes, herpes simplex otitis externa, 
> and herpes virus infection, but excludes eczema herpeticum.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 14, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=14)

<a id="dupixent-conjunctivitis"></a>

### Does Dupixent cause conjunctivitis or other eye side effects?

> “In adult subjects with AD, conjunctivitis was reported in 10% (34 per 100 patient-years) in the 
> 300 mg Q2W dose group and in 2% of the placebo group (8 per 100 patient-years) during the 16-
> week treatment period of the monotherapy trials (SOLO 1, SOLO 2, and AD-1021). During the 
> 52-week treatment period of concomitant therapy AD trial (CHRONOS), conjunctivitis was 
> reported in 16% of the DUPIXENT 300 mg Q2W + TCS group (20 per 100 patient-years) and in 
> 9% of the placebo + TCS group (10 per 100 patient-years). During the long-term OLE trial with 
> data through 260 weeks (AD-1225), conjunctivitis was reported in 21% of the DUPIXENT 
> group (12 per 100 patient-years). 
> In DUPIXENT AD monotherapy trials (SOLO 1, SOLO 2, and AD-1021) through Week 16, 
> keratitis was reported in <1% of the DUPIXENT group (1 per 100 patient-years) and in 0% of 
> the placebo group (0 per 100 patient-years). In the 52-week DUPIXENT + topical corticosteroids 
> (TCS) AD trial (CHRONOS), keratitis was reported in 4% of the DUPIXENT + TCS group (4 
> per 100 patient-years) and in 2% of the placebo + TCS group (2 per 100 patient-years). 
> Conjunctivitis and keratitis occurred more frequently in AD subjects who received DUPIXENT. 
> Conjunctivitis was the most frequently reported eye disorder. During the long-term OLE trial 
> with data through 260 weeks (AD-1225), keratitis was reported in 3% of the DUPIXENT group 
> (1 per 100 patient-years). Most subjects with conjunctivitis or keratitis recovered or were 
> recovering during the treatment period.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 22, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=22)

> “Conjunctivitis, Keratitis, and Blepharitis: Conjunctivitis and keratitis occurred more frequently in AD, COPD, and BP subjects who received DUPIXENT versus placebo, with conjunctivitis being the most frequently reported eye disorder in AD. Conjunctivitis also occurred more frequently in adult CRSwNP and PN subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis, keratitis, and blepharitis have been reported with DUPIXENT in postmarketing settings, predominantly in AD patients. Some patients reported varying degrees of transient or ongoing visual impairment including blindness associated with conjunctivitis, keratitis, or blepharitis leading to discontinuation of DUPIXENT and/or surgical intervention. Advise patients or their caregivers to promptly report new-onset or worsening eye symptoms to their healthcare provider. Consider discontinuation of DUPIXENT and prompt ophthalmological examination for patients who develop signs and symptoms suggestive of keratitis, or when conjunctivitis or blepharitis do not resolve following standard treatment, as appropriate. Use with caution in patients with significant dry eye disease, history of significant lid abnormalities/surgeries, or history of nasolacrimal surgery.”

Source: [DUPIXENT: Adult Clinical Trial Safety Profile, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/safety-clinical-trial#:~:text=Conjunctivitis%2C%20Keratitis%2C%20and%20Blepharitis%3A%20Conjunctivitis,or%20history%20of%20nasolacrimal%20surgery.)

<a id="dupixent-injection-site-reactions"></a>

### How common are injection site reactions with Dupixent in atopic dermatitis?

> “Table 9: 
> Adverse Reactions Occurring in ≥1% of the DUPIXENT Monotherapy 
> Group or the DUPIXENT + TCS Group in the Atopic Dermatitis Trials 
> through Week 16 
> Adverse Reaction 
> DUPIXENT Monotherapy<sup>a</sup> 
> DUPIXENT + TCS<sup>b</sup> 
> DUPIXENT 
> 300 mg Q2W<sup>c</sup> 
>
> N=529 
> n (%) 
> Placebo 
>
>
> N=517 
> n (%) 
> DUPIXENT 
> 300 mg Q2W<sup>c</sup> + TCS 
>
> N=110 
> n (%) 
> Placebo + 
> TCS 
>
> N=315 
> n (%) 
> Injection site reaction 
> 51 (10) 
> 28 (5) 
> 11 (10) 
> 18 (6)”

Source: [DUPIXENT: dupixent_fpi.pdf, page 14, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=14)

> “Incidence of injection site reactions at 5 years was 14.70 events/100 patient-years<sup>2,a</sup>”

Source: [DUPIXENT: Adult Clinical Trial Safety Profile, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/safety-clinical-trial#:~:text=Incidence%20of%20injection%20site%20reactions%20at%205%20years%20was%2014.70%20events%2F100)

> “The safety data in AD-1225 reflect exposure to DUPIXENT 200 mg QW, 
> 300 mg QW and 300 mg Q2W in 2677 subjects, including 2254 exposed for at least 52 weeks, 
> 1224 exposed for at least 100 weeks, 561 exposed for at least 148 weeks and 179 exposed for at 
> least 260 weeks.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 13, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=13)

<a id="dupixent-herpes"></a>

### Does Dupixent raise the risk of eczema herpeticum or shingles (herpes zoster)?

> “Eczema Herpeticum and Herpes Zoster 
> The rate of eczema herpeticum was similar in the placebo and DUPIXENT groups in the AD 
> trials. The rates remained stable through 260 weeks in the long-term OLE trial (AD-1225). 
> Herpes zoster was reported in <1% of the DUPIXENT groups (1 per 100 patient-years) and in 
> <1% of the placebo group (1 per 100 patient-years) in the 16-week AD monotherapy trials. In the 
> 52-week DUPIXENT + TCS AD trial, herpes zoster was reported in 1% of the DUPIXENT + 
> TCS group (1 per 100 patient-years) and 2% of the placebo + TCS group (2 per 100 patient-
> years). During the long-term OLE trial with data through 260 weeks (AD-1225), 2.0% of 
> DUPIXENT-treated subjects reported herpes zoster (0.94 per 100 patient-years of follow up).”

Source: [DUPIXENT: dupixent_fpi.pdf, page 23, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=23)

<a id="dupixent-eosinophilia"></a>

### Does Dupixent raise eosinophil counts in patients with atopic dermatitis?

> “Treatment-emergent eosinophilia (≥5000 cells/mcL) was reported in<sup>1</sup>:
>
> <3% of DUPIXENT-treated subjects and <0.5% of placebo-treated subjects (SOLO 1, SOLO 2, and AD-1021; DRI12544, QUEST, and VOYAGE; SINUS-24 and SINUS-52; PRIME and PRIME2; BOREAS and NOTUS; CUPID-A, CUPID-B, and CUPID-C)<sup>g</sup>
> 8% of DUPIXENT-treated subjects and 0% of placebo-treated subjects (AD-1539)”

Source: [DUPIXENT: Adult Clinical Trial Safety Profile, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/safety-clinical-trial#:~:text=Treatment%2Demergent%20eosinophilia%20%28%E2%89%A55000%20cells%2FmcL%29%20was,0%25%20of%20placebo%2Dtreated%20subjects%20%28AD%2D1539%29)

> “DUPIXENT-treated subjects with AD, asthma, CRSwNP, and COPD had a greater initial 
> increase from baseline in blood eosinophil count compared to subjects receiving placebo. In 
> adult subjects with AD (SOLO 1, SOLO 2, and AD-1021), the mean and median increases in 
> blood eosinophils from baseline to Week 4 were 100 and 0 cells/mcL, respectively.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 23, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=23)

> “Across the trials for AD, asthma, CRSwNP, CSU, and AFRS indications, the incidence of 
> treatment-emergent eosinophilia (≥500 cells/mcL) was similar in DUPIXENT and placebo 
> groups.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 24, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=24)

<a id="dupixent-long-term-safety-adults"></a>

### What are the long-term side effects of Dupixent in adults with atopic dermatitis?

> “Long-term safety profile through ≈5 years<sup>1</sup>
>
> was generally consistent with AD controlled studies”

Source: [DUPIXENT: Adult Clinical Trial Safety Profile, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/safety-clinical-trial#:~:text=Long%2Dterm%20safety%20profile%20through%20%E2%89%885,consistent%20with%20AD%20controlled%20studies)

> “AD-1225 is a multicenter, open-label extension (OLE) trial which assessed the long-term safety 
> of repeat doses of DUPIXENT through 260 weeks of treatment in adults with moderate-to-severe 
> AD who had previously participated in controlled trials of DUPIXENT or had been screened for 
> SOLO 1 or SOLO 2. The safety data in AD-1225 reflect exposure to DUPIXENT 200 mg QW, 
> 300 mg QW and 300 mg Q2W in 2677 subjects, including 2254 exposed for at least 52 weeks, 
> 1224 exposed for at least 100 weeks, 561 exposed for at least 148 weeks and 179 exposed for at 
> least 260 weeks.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 13, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=13)

> “Safety through Week 52 (CHRONOS) 
> In the DUPIXENT with concomitant TCS trial (CHRONOS) through Week 52, the proportion of 
> subjects who discontinued treatment because of adverse events was 1.8% in DUPIXENT 300 mg 
> Q2W + TCS group and 7.6% in the placebo + TCS group. Two subjects discontinued 
> DUPIXENT because of adverse reactions: atopic dermatitis (1 subject) and exfoliative dermatitis 
> (1 subject). 
> The safety profile of DUPIXENT + TCS through Week 52 was generally consistent with the 
> safety profile observed at Week 16. 
> Safety through 260 Weeks (AD-1225) 
> The long-term safety profile observed in this trial through 260 weeks was generally consistent 
> with the safety profile of DUPIXENT observed in controlled studies.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 14, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=14)

> “During the long-term OLE trial with 
> data through 260 weeks (AD-1225), conjunctivitis was reported in 21% of the DUPIXENT 
> group (12 per 100 patient-years).”

Source: [DUPIXENT: dupixent_fpi.pdf, page 22, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=22)

> “During the long-term OLE trial 
> with data through 260 weeks (AD-1225), keratitis was reported in 3% of the DUPIXENT group 
> (1 per 100 patient-years).”

Source: [DUPIXENT: dupixent_fpi.pdf, page 22, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=22)

> “During the long-term OLE trial with data through 260 weeks (AD-1225), 2.0% of 
> DUPIXENT-treated subjects reported herpes zoster (0.94 per 100 patient-years of follow up).”

Source: [DUPIXENT: dupixent_fpi.pdf, page 23, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=23)

> “Incidence of injection site reactions at 5 years was 14.70 events/100 patient-years<sup>2,a</sup>”

Source: [DUPIXENT: Adult Clinical Trial Safety Profile, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/safety-clinical-trial#:~:text=Incidence%20of%20injection%20site%20reactions%20at%205%20years%20was%2014.70%20events%2F100)

<a id="dupixent-pediatric-safety"></a>

### What side effects does Dupixent have in children and infants with atopic dermatitis?

> “The safety profile of DUPIXENT in pediatric patients through Week 16 was similar to that in adults<sup>1</sup>”

Source: [DUPIXENT: Pediatric Safety Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/pediatric-safety-data#:~:text=The%20safety%20profile%20of%20DUPIXENT,was%20similar%20to%20that%20in)

> “The safety profile in pediatric patients through Week 16<sup>a</sup> and Week 52<sup>b</sup> was consistent with that of adults with AD<sup>1</sup>
> In AD-1434, hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) were reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation”

Source: [DUPIXENT: Pediatric Safety Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/pediatric-safety-data#:~:text=The%20safety%20profile%20in%20pediatric,lead%20to%20study%20drug%20discontinuation)

> “In an open-label extension trial, AD-1434.”

Source: [DUPIXENT: Pediatric Safety Data| DUPIXENT® (dupilumab), captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/pediatric-safety-data#:~:text=In%20an%20open%2Dlabel%20extension%20trial%2C%20AD%2D1434.)

> “The safety of DUPIXENT with concomitant TCS was assessed in a trial of 161 pediatric subjects 
> 6 months to 5 years of age with moderate-to-severe AD (AD-1539). The safety profile of 
> DUPIXENT + TCS in these subjects through Week 16 was similar to the safety profile from 
> trials in adults and pediatric subjects 6 years of age and older with AD. 
> The long-term safety of DUPIXENT ± TCS was assessed in an open-label extension study of 
> 180 pediatric subjects 6 months to 5 years of age with AD (AD-1434). The majority of subjects 
> were treated with DUPIXENT 300 mg every 4 weeks. The safety profile of DUPIXENT ± TCS 
> in subjects followed through Week 52 was similar to the safety profile observed through Week 
> 16 in AD-1539. The long-term safety profile of DUPIXENT ± TCS observed in pediatric 
> subjects 6 months to 5 years of age was consistent with that seen in adults and pediatric subjects 
> 6 years of age and older with AD. In addition, hand-foot-and-mouth disease was reported in 9 
> (5%) pediatric subjects and skin papilloma was reported in 4 (2%) pediatric subjects treated with 
> DUPIXENT ± TCS. These cases did not lead to study drug discontinuation.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 15, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=15)

<a id="dupixent-contraindications"></a>

### Who should not take Dupixent (contraindications)?

> “CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.”

Source: [DUPIXENT: Adult Clinical Trial Safety Profile, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/safety-clinical-trial#:~:text=CONTRAINDICATION%3A%20DUPIXENT%20is%20contraindicated%20in,or%20any%20of%20its%20excipients.)

<a id="dupixent-boxed-warning"></a>

### Does Dupixent have a boxed warning?

> “DUPIXENT does not have a boxed warning.<sup>1</sup>”

Source: [DUPIXENT: FAQs About DUPIXENT® (dupilumab) for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/about/frequently-asked-questions#:~:text=DUPIXENT%20does%20not%20have%20a%20boxed)

On the page, select: Does DUPIXENT have a boxed warning?

<a id="dupixent-overdose"></a>

### What should be done after a Dupixent overdose?

> “There is no specific treatment for DUPIXENT overdose. In the event of overdosage, contact 
> Poison Control (1-800-222-1222) for the latest recommendations and monitor the patient for any 
> signs or symptoms of adverse reactions and institute appropriate symptomatic treatment 
> immediately.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 31, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=31)

## Warnings

<a id="dupixent-hypersensitivity"></a>

### Can Dupixent cause allergic reactions or anaphylaxis?

> “Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, acute generalized exanthematous pustulosis (AGEP), serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. A case of AGEP was reported in an adult subject who participated in the bullous pemphigoid development program. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.”

Source: [DUPIXENT: Adult Clinical Trial Safety Profile, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/safety-clinical-trial#:~:text=Hypersensitivity%3A%20Hypersensitivity%20reactions%2C%20including%20anaphylaxis%2C,appropriate%20therapy%20and%20discontinue%20DUPIXENT.)

> “Hypersensitivity reactions were reported in <1% of DUPIXENT-treated subjects. These included 
> anaphylaxis, AGEP, serum sickness or serum sickness-like reactions, generalized urticaria, rash, 
> erythema nodosum, and erythema multiforme [see Contraindications (4) and Clinical 
> Pharmacology (12.6)].”

Source: [DUPIXENT: dupixent_fpi.pdf, page 23, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=23)

<a id="dupixent-psoriasis-arthralgia"></a>

### Can Dupixent cause psoriasis, joint pain, or psoriatic arthritis?

> “Psoriasis: Cases of new-onset psoriasis have been reported with the use of DUPIXENT for the treatment of atopic dermatitis and asthma, including in patients without a family history of psoriasis. In postmarketing reports, these cases resulted in partial or complete resolution of psoriasis with discontinuation of dupilumab, with or without use of supplemental treatment for psoriasis (topical or systemic). Those who continued dupilumab received supplemental treatment for psoriasis to improve associated symptoms. Advise patients to report new-onset psoriasis symptoms. If symptoms persist or worsen, consider dermatologic evaluation and/or discontinuation of DUPIXENT.
>
> Arthralgia and Psoriatic Arthritis: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Cases of new-onset psoriatic arthritis requiring systemic treatment have been reported with the use of DUPIXENT. Advise patients to report new-onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.”

Source: [DUPIXENT: Adult Clinical Trial Safety Profile, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/safety-clinical-trial#:~:text=Psoriasis%3A%20Cases%20of%20new%2Donset%20psoriasis,rheumatological%20evaluation%20and%2For%20discontinuation%20of%20DUPIXENT.)

<a id="dupixent-helminth"></a>

### Should parasitic (helminth) infections be treated before starting Dupixent?

> “Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves. Helminth infections (5 cases of enterobiasis and 1 case of ascariasis) were reported in pediatric patients 6 to 11 years old in the pediatric asthma development program.”

Source: [DUPIXENT: Adult Clinical Trial Safety Profile, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/safety-clinical-trial#:~:text=Parasitic%20%28Helminth%29%20Infections%3A%20It%20is,the%20pediatric%20asthma%20development%20program.)

<a id="dupixent-corticosteroid-reduction"></a>

### Can patients stop corticosteroids or asthma medicines when they start Dupixent?

> “Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.
>
> Patients with Co-morbid Asthma: Advise patients with co-morbid asthma not to adjust or stop their asthma treatments without consultation with their physicians.”

Source: [DUPIXENT: Adult Clinical Trial Safety Profile, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/safety-clinical-trial#:~:text=Risk%20Associated%20with%20Abrupt%20Reduction,without%20consultation%20with%20their%20physicians.)

## Monitoring

<a id="dupixent-lab-monitoring"></a>

### Does Dupixent require lab tests before or during treatment?

> “DUPIXENT does not require initial lab testing or ongoing lab monitoring, according to the Prescribing Information<sup>1</sup>”

Source: [DUPIXENT: DUPIXENT® (dupilumab) Dosage for Uncontrolled Moderate-to-Severe Atopic Dermatitis, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/dosage-administration#:~:text=DUPIXENT%20does%20not%20require%20initial,monitoring%2C%20according%20to%20the%20Prescribing)

## Vaccines

<a id="dupixent-vaccines"></a>

### Can patients on Dupixent get vaccines?

> “Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines during treatment with DUPIXENT.”

Source: [DUPIXENT: Adult Clinical Trial Safety Profile, captured 2026-11-12](https://www.dupixenthcp.com/atopicdermatitis/efficacy-safety/safety-clinical-trial#:~:text=Vaccinations%3A%20Consider%20completing%20all%20age%2Dappropriate,vaccines%20during%20treatment%20with%20DUPIXENT.)

> “It is unknown if administration of live vaccines during DUPIXENT 
> treatment will impact the safety or effectiveness of these vaccines. Limited data are available 
> regarding coadministration of DUPIXENT with non-live vaccines [see Clinical Pharmacology 
> (12.2)].”

Source: [DUPIXENT: dupixent_fpi.pdf, page 12, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=12)

> “Antibody Response to Non-Live Vaccines During DUPIXENT Treatment 
> In a clinical study, adult subjects with AD were treated once weekly for 16 weeks with 300 mg 
> of DUPIXENT (twice the recommended dosing frequency). After 12 weeks of administration, 
> subjects received a Tdap vaccine and a meningococcal polysaccharide vaccine. Antibody 
> responses to tetanus toxoid and serogroup C meningococcal polysaccharide were assessed 
> 4 weeks later. Antibody responses to both tetanus toxoid and serogroup C meningococcal 
> polysaccharide were similar in DUPIXENT-treated and placebo-treated subjects. Antibody 
> responses to the other active components of both vaccines were not assessed. Antibody responses 
> to other non-live vaccines were also not assessed.”

Source: [DUPIXENT: dupixent_fpi.pdf, page 32, captured 2026-11-12](https://www.regeneron.com/downloads/dupixent_fpi.pdf#page=32)

## Related pages
- [Medical information: Dupixent (dupilumab): Atopic dermatitis](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis)
- [Indication](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/real-world-evidence)
- [Specific populations](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/dupixent--atopic-dermatitis/guidelines)
